With its activities primarily focused on the Turkish market and selected countries, Biem is an important partner in the pharmaceutical industry. As Biem, we are aware that strong collaborations are a key driver of success. We are committed to continuous and strategic growth by establishing mutually beneficial partnerships through the acquisition and commercialization of targeted products.
Business Development
Strategic
Growth
Terapeutic Areas
Focusing various therapeutic areas, Biem gives additional priority to Oncology, Hematology, Ophthalmology, and Radiology, and approaches prescription-only medicines and orphan drugs with particular care and sensitivity.
Our Future Objectives
Biem continues to evaluate product opportunities aligned with it’s areas of expertise and to develop future business objectives. Biem pursues collaborations with the aim of developing new treatments for diseases at both local and global levels.
Business Development
Biem continues to advance and grow in the sector by steadily increasing it’s efforts—both independently and in collaboration with companies that share the same goal—to bring new products to the market, promote them, and further develop products that are already available in the market.
Being Focused on Quality
Biem’s contract manufacturers with whom it collaborates, hold GMP certification issued by the TMMDA, which is a member of PIC/S. In addition, Biem’s contract manufacturers also carry out their production in EU GMP-certified manufacturing facilities.